The quarter was close to expectations on sales but better on reported ADS loss. The published consensus available before the release was approximately $107.9 million of revenue and a $0.61 ADS loss; Zai Lab delivered $106.3 million of revenue and a $0.46 ADS loss. That means a modest revenue miss but a clearer-than-expected EPS beat.
| $ millions, except per-ADS data | Q2 2026 | Q2 2025 | Consensus / comparison |
|---|---|---|---|
| Total revenue | 106.3 | 110.0 | ~107.9 consensus |
| Net product revenue | 105.8 | 109.1 | — |
| GAAP loss from operations | (76.5) | (54.9) | — |
| Adjusted loss from operations | (60.4) | (34.2) | — |
| Net loss | (50.8) | (40.7) | — |
| Loss per ADS | (0.46) | (0.37) | ~(0.61) consensus |
| Cash and cash equivalents | 607.5 | — | 679.6 at Dec. 31, 2025 |
Underlying operating performance remained weak despite the EPS beat. Product revenue fell 3% year over year, while GAAP loss from operations widened to $76.5 million from $54.9 million and adjusted operating loss widened to $60.4 million from $34.2 million. Higher licensing fees drove much of the deterioration, so the better-than-expected per-ADS loss does not represent a comparable improvement in the core business. (Income Statement) (Adjusted loss from operations reconciliation)
The sequential recovery is real but not yet a return to growth. Product revenue rose 11% from the prior quarter, helped by ZEJULA stabilization and double-digit VYVGART volume growth, but management is still describing meaningful commercial growth as a 2027 event. That makes this more of a stabilization update than a changed near-term earnings trajectory. (Financial Highlights)
Pipeline execution was reaffirmed rather than materially upgraded. Zoci remains on track for a potential first-line SCLC Phase 3 start later in 2026, second-line-plus enrollment completion in the first half of 2027, and possible U.S. accelerated-approval filing in 2027; ZL-1503 data remain expected in the second half of 2026. These are important catalysts, but the filing largely repeats timing already communicated rather than delivering clinical proof or pulling milestones forward. (Pipeline and Corporate Updates)
Financial flexibility is narrowing while investment rises. Cash and cash equivalents declined to $607.5 million from $679.6 million at year-end, short-term debt increased to $238.1 million from $204.5 million, and first-half adjusted operating loss reached $112.3 million. The filing therefore leaves the near-term commercial picture mixed: pipeline progress supports the longer-term story, but revenue is still shrinking year over year and cash consumption remains substantial. (Balance Sheet) (Income Statement) (Adjusted loss from operations reconciliation)
Read the original 8-K on SEC EDGAR ↗